Literature DB >> 9271021

Hodgkin's cells express CD83, a dendritic cell lineage associated antigen.

U R Sorg1, T M Morse, W N Patton, B D Hock, H B Angus, B A Robinson, B M Colls, D N Hart.   

Abstract

Hodgkin's cells (HC) are considered to be the malignant cells of Hodgkin's disease (HD), but despite extensive studies, no conclusive evidence has emerged regarding their non-malignant counterpart and the ontogeny of these cells remains controversial. The analysis of a possible dendritic cell (DC) origin of HC has been hampered to date by the lack of a DC lineage specific marker. The expression of the two DC-associated antigens CD83 and CMRF-44, the B lymphocyte restricted molecule CD79, and the costimulator molecule CD86, was examined in lymph nodes from 23 HD patients using immunohistological techniques. The majority of HC expressed the CD83 (22/23) and CD86 antigens (20/23), whereas expression of the CMRF-44 antigen was variable (10/23) and usually only a subpopulation of HC stained. In contrast, the CD79 antigen was absent from most HC (17/23). The presence of the CD83 antigen on HC in the absence of the CD79 antigen supports a possible DC lineage origin for some HC. Regardless of its role in lineage assignment, CD83 may become a useful immunohistological marker for HD as the CD83 antigen was present on most HC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271021     DOI: 10.1080/00313029700169125

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  10 in total

1.  A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells.

Authors:  K Uehira; R Amakawa; T Ito; T Uehira; Y Ozaki; T Shimizu; M Fujimoto; M Inaba; S Fukuhara
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  Dendritic cell CD83: a therapeutic target or innocent bystander?

Authors:  Charlene M Prazma; Thomas F Tedder
Journal:  Immunol Lett       Date:  2007-10-29       Impact factor: 3.685

3.  CD83 in Hodgkin lymphoma.

Authors:  Ralf Küppers
Journal:  Haematologica       Date:  2018-04       Impact factor: 9.941

Review 4.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

5.  Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.

Authors:  Ziduo Li; Edward Abadir; Kenneth Lee; Candice Clarke; Christian E Bryant; Wendy Cooper; Geoffrey Pietersz; James Favaloro; Pablo A Silveira; Derek Nj Hart; Xinsheng Ju; Georgina J Clark
Journal:  Clin Transl Immunology       Date:  2020-07-15

6.  Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway.

Authors:  Diana Dudziak; Arnd Kieser; Ulrike Dirmeier; Falk Nimmerjahn; Susanne Berchtold; Alexander Steinkasserer; Gabriele Marschall; Wolfgang Hammerschmidt; Gerhard Laux; Georg W Bornkamm
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 7.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

8.  CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Authors:  Ziduo Li; Xinsheng Ju; Kenneth Lee; Candice Clarke; Jennifer L Hsu; Edward Abadir; Christian E Bryant; Suzanne Pears; Neroli Sunderland; Scott Heffernan; Annemarie Hennessy; Tsun-Ho Lo; Geoffrey A Pietersz; Fiona Kupresanin; Phillip D Fromm; Pablo A Silveira; Con Tsonis; Wendy A Cooper; Ilona Cunningham; Christina Brown; Georgina J Clark; Derek N J Hart
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

Review 9.  CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Authors:  Ziduo Li; Xinsheng Ju; Pablo A Silveira; Edward Abadir; Wei-Hsun Hsu; Derek N J Hart; Georgina J Clark
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

10.  Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.

Authors:  Michael Hinz; Petra Lemke; Ioannis Anagnostopoulos; Christine Hacker; Daniel Krappmann; Stephan Mathas; Bernd Dörken; Martin Zenke; Harald Stein; Claus Scheidereit
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.